SCHEMBL2826701

SCHEMBL2826701

COc1ccc(-c2nnc3c4ccccc4c(Nc4ccc(C(=O)N5CCN(C)CC5)cc4)nn23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
NPSR1 Q6W5P4 2/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
RAB9A P51151 1/20 0.50
POLB P06746 2/20 0.49
TP53 P04637 3/20 0.49
SMO Q99835 1/20 0.47
FLT3 P36888 1/20 0.47
HPGD P15428 3/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825342 0.91 MAPT (0.51) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2828929 0.91 MAPT (0.48) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2828751 0.91 HPGD (0.58) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2827153 0.86 MAPT (0.58) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2026001 0.86 MAPT (0.55) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2825087 0.85 MAPT (0.57) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2832045 0.85 MAPT (0.56) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2824919 0.85 KDR (0.64) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2825724 0.85 MAPT (0.56) MAPTSMN1; SMN2NPSR1NPC1LMNA
SCHEMBL2828235 0.85 MAPT (0.56) MAPTSMN1; SMN2NPSR1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US claimed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US claimed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP claimed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US claimed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP claimed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO claimed
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A MAPT 3816/4885SMN1; SMN2 2985/4885NPSR1 637/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A MAPT 3816/4885SMN1; SMN2 2985/4885NPSR1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.